Speaker Profile

PMWC LUMINARY AWARD
Pioneering work in cancer immunotherapies

Ph.D., Barbara and Edward Netter Professor in Cancer Gene Therapy, UPenn

Biography
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 30 issued US patents and co-author of >200 manuscripts and book chapters with a Google Scholar citation h-index of 100. He is a Co-Founder of Tmunity Therapeutics, and of Capstan Therapeutics both spinouts of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as Immediate Past-President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.


 Session Abstract – PMWC 2023 Silicon Valley

Track 1 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: Sharon Benzeno, Adaptive Biotechnologies

  • PMWC 2023 Luminary Award Ceremony
    Honoree: Bruce Levine, University of Pennsylvania
  • Advance and Optimize Cell Therapies in Oncology (PANEL)
    Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Ira Mellman, Genenetch
    - Mark Selby, Walking Fish Therapeutics
    - Sneha Ramakrishna, Stanford
    - Loïc VINCENT, Affini-T Therapeutics
    - Nick Haining, Arsenal
    - Warner Biddle, Kite
  • Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
    Chair: Carl June, UPenn
    - Lenny Dragone, Sonoma
    - James Chung, Kyverna
    - David Chang, Cabaletta
    - Cristina Musselli, Abata Therapeutics
  • Innovations in Cell Therapy Manufacturing (PANEL)
    Chair: Bruce Levine, University of Pennsylvania
    - Chris Holt, BMS
    - Heidi Hagen, Sonoma Bio
    - Rahul Singhvi, Resilience
    - Snehal Patel, Sana Biotechnology
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Investing in Gene-Modified Cell Therapies
    Chair: Karen Tkach Tuzman, BioCentury Inc.
    - Robert Lin, UPMC
    - Yvonne Yamanaka, venBio
    - Abraham Bassan, Samsara Capital
    - Brian Daniels, 5am Ventures
  • Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
    Chair: Jason Coloma, Maze Therapeutics
    - Peter DiLaura, Sonoma Bio
    - Nick Haining, Arsenal
    - Kwame Okrah, Parker Institute
    - Dan Kirouac, Notch Therapeutics